Nifty
Sensex
:
:
13055.15
44523.02
128.70 (1.00%)
445.87 (1.01%)

Pharmaceuticals & Drugs - Global

Rating :
65/99  (View)

BSE: 524715 | NSE: SUNPHARMA

520.15
7.30 (1.42%)
24-Nov-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  513.50
  •  522.75
  •  508.20
  •  512.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  9096230
  •  47314.04
  •  564.75
  •  312.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 123,037.90
  • 83.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 124,865.23
  • 0.78%
  • 2.73

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.69%
  • 3.40%
  • 7.51%
  • FII
  • DII
  • Others
  • 12.38%
  • 19.67%
  • 2.35%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.08
  • 3.16
  • 7.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.63
  • -3.09
  • 4.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.59
  • -3.62
  • 21.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 37.76
  • 33.98
  • 39.00

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.10
  • 3.66
  • 2.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.73
  • 16.52
  • 15.99

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
8,553
8,123
5%
7,585
8,374
-9%
8,185
7,164
14%
8,155
7,740
5%
Expenses
6,360
6,342
0%
5,821
6,446
-10%
6,822
6,147
11%
6,395
5,814
10%
EBITDA
2,193
1,781
23%
1,764
1,928
-8%
1,363
1,017
34%
1,760
1,926
-9%
EBIDTM
26%
22%
4%
4%
14%
14%
22%
25%
Other Income
256
209
22%
233
280
-17%
102
282
-64%
202
420
-52%
Interest
33
84
-60%
52
104
-50%
52
150
-65%
63
145
-57%
Depreciation
499
473
5%
496
457
8%
575
454
27%
547
471
16%
PBT
1,917
1,433
34%
15
15
0%
577
694
-17%
1,351
1,730
-22%
Tax
-31
266
-
1
1
0%
83
-29
-
328
271
21%
PAT
1,948
1,167
67%
14
14
0%
494
723
-32%
1,024
1,459
-30%
PATM
23%
14%
37%
37%
7%
7%
13%
19%
EPS
8.12
4.87
67%
0.06
0.06
0%
2.06
3.01
-32%
4.27
6.08
-30%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
32,478
32,838
29,066
26,416
31,308
28,109
27,392
16,080
11,300
8,019
5,728
Net Sales Growth
3%
13%
10%
-16%
11%
3%
70%
42%
41%
40%
 
Cost Of Goods Sold
9,013
9,230
7,869
7,352
8,164
6,170
6,733
2,778
2,076
1,648
1,460
Gross Profit
23,465
23,607
21,197
19,064
23,144
21,938
20,659
13,303
9,224
6,372
4,268
GP Margin
72%
72%
73%
72%
74%
78%
75%
83%
82%
79%
74%
Total Expenditure
25,398
25,863
22,792
20,881
21,626
19,950
19,616
9,121
6,438
4,836
3,785
Power & Fuel Cost
-
622
614
560
525
545
561
232
187
146
97
% Of Sales
-
2%
2%
2%
2%
2%
2%
1%
2%
2%
2%
Employee Cost
-
6,362
5,967
5,367
4,902
4,772
4,503
2,074
1,535
1,188
819
% Of Sales
-
19%
21%
20%
16%
17%
16%
13%
14%
15%
14%
Manufacturing Exp.
-
1,690
1,885
1,827
1,294
1,419
1,434
815
618
463
338
% Of Sales
-
5%
6%
7%
4%
5%
5%
5%
5%
6%
6%
General & Admin Exp.
-
3,341
2,729
2,862
3,114
2,957
2,895
978
793
629
481
% Of Sales
-
10%
9%
11%
10%
11%
11%
6%
7%
8%
8%
Selling & Distn. Exp.
-
3,654
2,621
1,865
2,521
2,262
2,236
1,395
763
517
372
% Of Sales
-
11%
9%
7%
8%
8%
8%
9%
7%
6%
6%
Miscellaneous Exp.
-
963
1,108
1,048
1,106
1,825
1,254
848
465
247
372
% Of Sales
-
3%
4%
4%
4%
6%
5%
5%
4%
3%
4%
EBITDA
7,080
6,974
6,274
5,535
9,682
8,158
7,776
6,959
4,862
3,183
1,943
EBITDA Margin
22%
21%
22%
21%
31%
29%
28%
43%
43%
40%
34%
Other Income
793
652
1,059
912
1,030
658
638
593
422
493
375
Interest
200
303
555
518
400
523
579
44
43
28
74
Depreciation
2,117
2,053
1,753
1,500
1,265
1,038
1,195
409
336
291
205
PBT
3,861
5,270
5,025
4,429
9,048
7,256
6,641
7,099
4,905
3,356
2,039
Tax
381
823
601
911
1,212
914
915
702
846
313
129
Tax Rate
10%
16%
16%
26%
13%
14%
14%
15%
20%
9%
6%
PAT
3,481
3,780
2,667
2,121
6,954
4,544
4,552
3,141
2,990
2,658
1,819
PAT before Minority Interest
3,245
4,187
3,209
2,568
7,836
5,657
5,488
3,879
3,476
3,043
1,911
Minority Interest
-236
-407
-542
-447
-882
-1,113
-936
-738
-486
-385
-91
PAT Margin
11%
12%
9%
8%
22%
16%
17%
20%
26%
33%
32%
PAT Growth
3%
42%
26%
-70%
53%
0%
45%
5%
12%
46%
 
EPS
14.51
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08
7.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
45,264
41,409
38,314
36,640
32,982
25,638
18,525
14,990
12,236
9,483
Share Capital
240
240
240
240
241
207
207
104
104
104
Total Reserves
45,025
41,169
38,074
36,397
32,736
25,374
18,318
14,886
12,132
9,380
Non-Current Liabilities
246
77
46
600
2,170
2,335
1,748
199
-225
-188
Secured Loans
257
109
218
186
8
41
44
42
50
4
Unsecured Loans
1,771
1,413
1,554
1,250
3,103
1,328
5
73
106
153
Long Term Provisions
511
430
404
1,211
1,896
2,532
2,602
787
139
13
Current Liabilities
15,706
17,340
19,864
17,887
13,144
16,147
5,990
2,841
2,618
1,731
Trade Payables
4,094
4,148
4,766
4,395
3,583
3,287
1,328
1,058
993
645
Other Current Liabilities
1,891
1,762
1,876
2,674
1,134
2,280
260
219
364
362
Short Term Borrowings
5,549
8,371
7,980
6,655
5,206
6,228
2,440
83
110
208
Short Term Provisions
4,172
3,059
5,242
4,163
3,221
4,353
1,961
1,482
1,153
515
Total Liabilities
65,077
62,139
62,109
58,917
52,381
46,972
28,184
19,665
15,790
11,873
Net Block
22,847
21,837
18,853
17,675
15,872
12,682
6,817
5,647
3,951
3,293
Gross Block
35,116
31,687
26,949
24,466
22,180
20,407
10,485
8,709
6,449
5,319
Accumulated Depreciation
12,269
9,850
8,096
6,791
6,308
7,724
3,668
3,062
2,497
2,026
Non Current Assets
33,423
31,070
30,473
25,964
22,440
18,056
9,498
8,162
5,497
4,280
Capital Work in Progress
1,220
1,411
2,465
2,801
2,175
2,039
842
563
345
235
Non Current Investment
5,246
3,952
3,052
961
1,116
599
788
1,106
589
346
Long Term Loans & Adv.
4,061
3,848
6,053
3,844
2,323
2,632
1,017
803
593
377
Other Non Current Assets
49
22
50
682
953
104
34
43
19
28
Current Assets
31,654
31,069
31,636
32,954
29,941
28,916
18,686
11,503
10,293
7,593
Current Investments
4,897
3,951
4,091
231
714
2,117
1,998
1,305
1,624
1,884
Inventories
7,875
7,886
6,881
6,833
6,423
5,668
3,123
2,578
2,087
1,489
Sundry Debtors
9,421
8,884
7,815
7,203
6,776
5,106
2,200
2,412
2,079
1,105
Cash & Bank
6,488
7,276
9,929
15,141
13,182
10,998
7,590
4,059
3,367
2,205
Other Current Assets
2,973
1,266
891
718
2,848
5,026
3,774
1,149
1,137
910
Short Term Loans & Adv.
1,432
1,806
2,029
2,828
2,317
1,921
1,094
953
977
784
Net Current Assets
15,948
13,730
11,772
15,067
16,797
12,769
12,697
8,662
7,675
5,862
Total Assets
65,077
62,139
62,109
58,917
52,381
46,972
28,184
19,665
15,790
11,873

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
6,555
2,196
3,907
7,082
6,686
5,616
3,959
3,357
2,234
2,283
PBT
5,010
3,810
3,479
9,048
6,571
6,403
4,581
4,315
3,355
2,036
Adjustment
1,993
1,969
1,382
501
1,857
774
-40
160
111
-171
Changes in Working Capital
899
-2,696
-212
-409
247
180
207
-45
-1,005
488
Cash after chg. in Working capital
7,901
3,083
4,649
9,139
8,674
7,356
4,748
4,430
2,461
2,352
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-1,346
-886
-742
-2,057
-1,988
-1,740
-789
-1,073
-227
-69
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-2,589
-681
-3,371
-4,222
-4,372
-2,866
-2,367
-2,635
-863
-1,848
Net Fixed Assets
-737
-543
-1,472
-1,217
2,214
-4,632
-381
-341
-267
-212
Net Investments
542
451
978
3,038
3,504
-18,860
-2,698
120
-836
450
Others
-2,394
-589
-2,877
-6,043
-10,090
20,626
712
-2,414
241
-2,085
Cash from Financing Activity
-5,715
-2,731
-1,539
-2,285
-1,889
-1,187
507
-665
-544
-804
Net Cash Inflow / Outflow
-1,749
-1,215
-1,003
575
426
1,563
2,099
57
827
-369
Opening Cash & Equivalents
7,062
7,906
8,642
8,032
7,183
4,359
2,069
1,753
810
634
Closing Cash & Equivalent
5,677
7,062
7,906
8,642
8,032
7,286
4,359
2,069
1,753
810

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
189
173
160
153
137
123
89
72
59
46
ROA
7%
5%
4%
14%
11%
15%
16%
20%
22%
18%
ROE
10%
8%
7%
23%
19%
25%
23%
26%
28%
22%
ROCE
10%
9%
8%
21%
19%
25%
25%
31%
30%
24%
Fixed Asset Turnover
1.78
1.92
1.99
1.35
1.34
1.79
1.70
1.51
1.38
1.44
Receivable days
56
54
54
81
76
48
52
71
71
72
Inventory Days
48
48
49
77
77
58
64
74
80
80
Payable days
63
78
90
78
75
52
56
65
65
51
Cash Conversion Cycle
41
24
12
80
78
54
59
81
87
101
Total Debt/Equity
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
Interest Cover
18
8
8
24
14
12
105
101
120
29

News Update


  • Sun Pharma recalling 747 bottles of generic diabetes drug in US market
    12th Oct 2020, 09:57 AM

    The company is recalling the bottles of RIOMET ER in the American market

    Read More
  • Sun Pharma looking to expand specialty business across different regions
    28th Sep 2020, 09:29 AM

    The company's strategy of developing the specialty business as an additional growth engine has started delivering results, with a gradual ramp up in specialty revenues

    Read More
  • Sun Pharma’s arm recalling one lot of Riomet ER oral suspension in US market
    25th Sep 2020, 09:45 AM

    This recall is being conducted with the knowledge of the USFDA

    Read More
  • Sun Pharma’s arm launches ILUMYA Subcutaneous Injection in Japan
    23rd Sep 2020, 09:17 AM

    ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.